A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

NCT01150448 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Paliperidone palmitate Treatment A
DRUG: Paliperidone palmitate Treatment B

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.